JP2023516595A5 - - Google Patents
Info
- Publication number
- JP2023516595A5 JP2023516595A5 JP2022550927A JP2022550927A JP2023516595A5 JP 2023516595 A5 JP2023516595 A5 JP 2023516595A5 JP 2022550927 A JP2022550927 A JP 2022550927A JP 2022550927 A JP2022550927 A JP 2022550927A JP 2023516595 A5 JP2023516595 A5 JP 2023516595A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- genetically modified
- amino acid
- acid sequence
- modified host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982348P | 2020-02-27 | 2020-02-27 | |
| US62/982,348 | 2020-02-27 | ||
| US202063089869P | 2020-10-09 | 2020-10-09 | |
| US63/089,869 | 2020-10-09 | ||
| PCT/US2021/020089 WO2021174124A1 (en) | 2020-02-27 | 2021-02-26 | Dimeric antigen receptors (dar) that bind cd20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516595A JP2023516595A (ja) | 2023-04-20 |
| JP2023516595A5 true JP2023516595A5 (enExample) | 2024-03-06 |
Family
ID=77490527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550927A Pending JP2023516595A (ja) | 2020-02-27 | 2021-02-26 | Ｃｄ２０を結合する二量体抗原受容体（ｄａｒ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230061838A1 (enExample) |
| EP (1) | EP4110829A4 (enExample) |
| JP (1) | JP2023516595A (enExample) |
| CN (1) | CN115461377A (enExample) |
| CA (1) | CA3169158A1 (enExample) |
| WO (1) | WO2021174124A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117986387A (zh) * | 2023-05-31 | 2024-05-07 | 四川大学华西医院 | 一种新型小型化car设计及制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002096948A2 (en) * | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| CN108395482B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| KR20190133017A (ko) * | 2017-03-27 | 2019-11-29 | 에프. 호프만-라 로슈 아게 | 개선된 항원 결합 수용체 구성 |
| EP3729081B1 (en) * | 2017-12-21 | 2025-02-19 | F. Hoffmann-La Roche AG | Car-t cell assay for specificity test of novel antigen binding moieties |
| AU2019231315A1 (en) * | 2018-03-09 | 2020-09-17 | Vivasor, Inc. | Dimeric antigen receptors (DAR) |
-
2021
- 2021-02-26 JP JP2022550927A patent/JP2023516595A/ja active Pending
- 2021-02-26 CA CA3169158A patent/CA3169158A1/en active Pending
- 2021-02-26 EP EP21761626.7A patent/EP4110829A4/en not_active Withdrawn
- 2021-02-26 WO PCT/US2021/020089 patent/WO2021174124A1/en not_active Ceased
- 2021-02-26 CN CN202180031496.7A patent/CN115461377A/zh active Pending
-
2022
- 2022-08-16 US US17/820,165 patent/US20230061838A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stewart et al. | The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer | |
| JP7549621B2 (ja) | Ｏ－アセチル化ＧＤ２ガングリオシド（ＯＡｃＧＤ２）に対するヒト化抗体 | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| Kang et al. | Boosting therapeutic potency of antibodies by taming Fc domain functions | |
| White et al. | Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies | |
| JP6714620B2 (ja) | 標的化された／免疫調節性融合タンパク質およびそれを作製するための方法 | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| CN118459611A (zh) | Gprc5d嵌合抗原受体以及表达这些受体的细胞 | |
| JP7225135B2 (ja) | 腫瘍特異的細胞枯渇のための化合物及び方法 | |
| RU2016104130A (ru) | Биспецифичные конструкции, связывающие антигены cd3 и cd19 | |
| AU2017281034A1 (en) | CD3 binding antibodies | |
| CN116333138A (zh) | Pd-1结合分子和其使用方法 | |
| RS65595B1 (sr) | Antitela koja vezuju cd3 | |
| JP2024528665A5 (enExample) | ||
| JP2024511115A (ja) | ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体 | |
| JP2022546577A5 (enExample) | ||
| KR20210115435A (ko) | 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물 | |
| JP2023515055A5 (enExample) | ||
| CN116407626A (zh) | 用于调节免疫细胞衔接效应的手段和方法 | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| JP2023516595A5 (enExample) | ||
| US20230416364A1 (en) | Methods of redirecting of il-2 to target cells of interest | |
| Valerius et al. | Activated neutrophils as effector cells for bispecific antibodies | |
| WO2025081163A1 (en) | Compositions for the treatment of cancer | |
| US20250243274A1 (en) | Compositions for Redirecting Immunoglobulins to Immune Cells |